Efficacy of Bifeprunox in Patients With Schizophrenia

Phase 3TerminatedNCT00658645

H. Lundbeck A/S227 enrolled

Overview

The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.

Schizophrenia is a serious and disabling mental disorder that affects approximately 1% of the world's population. There are a number of antipsychotic drugs in use but none is ideal, in particular because their safety profile is complex and their effectiveness is limited. In particular, after having overcome acute exacerbations many patients continue to experience significant symptoms that prevent an adequate functioning. In the current study, patients suffering from schizophrenia and currently in a post-acute maintenance phase of the disease will be included. Non-treatment resistant patients will be included in the study, since they have partially responded to their current antipsychotic treatment but still have clinically significant symptoms and/or impairment of functioning in their daily life. The study is a 12-month study with an initial 12-week placebo-controlled, quetiapine-referenced phase. After this initial 12-week phase, the patients allocated to placebo will be switched to bifeprunox. In the final non-inferiority analysis of the 12-month data, the results from this study will be combined with the data from a similar study (11916A).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

227

Conditions

Schizophrenia

Interventions

BifeprunoxDRUG

20 mg daily, encapsulated tablets, orally, 12 months

PlaceboDRUG

Encapsulated tablets, orally, 12 weeks

QuetiapineDRUG

600 mg daily, encapsulated tablets, orally, 12 months

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Main inclusion criteria * The subject has a primary diagnosis of schizophrenia * The subject experiences clinically significant symptoms * The subject's medication remained stable for 8 weeks prior to screening * The subject is currently in the post-acute maintenance phase of his/her disease Exclusion Criteria: Main exclusion criteria * The subject is at significant risk of suicide * The subject is treatment resistant * The subject has experienced an acute exacerbation within 8 weeks prior screening * The subject is unlikely to comply with the protocol * The subject has a current diagnosis or a history of substance abuse

Locations (38)

BG002

Outcomes

Primary Outcomes

The difference in change from baseline to the 12-week time point between bifeprunox and placebo using the Positive and Negative Syndrome Scale (PANSS).

Time frame: 12 weeks

Secondary Outcomes

The difference in PANSS score at the 12-month time point between bifeprunox and quetiapine. Also, responder rate, time to response/withdrawal, global clinical assessments (CGI), assessment of depressive symptoms (CDSS) and health economic assessments

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.